AMARIN CORP PLCUK

Step 01 — Business Model

Amarin Corporation plc (AMRN)

Prepared: June 2026 | Classification: Facts unless noted | Step: 01 of 20

1. Business Description

Amarin Corporation plc is a specialty pharmaceutical company incorporated under the laws of England and Wales, headquartered in Dublin, Ireland with a U.S. operational office in Bridgewater, New Jersey [S1]. The company's commercial identity is defined entirely by a single approved product: VASCEPA (icosapent ethyl, or IPE), a prescription-only pharmaceutical-grade purified form of eicosapentaenoic acid (EPA), the omega-3 fatty acid. Outside the United States, the same product is marketed as VAZKEPA. Amarin is, in the most literal sense, a one-product company — its financial results, clinical pipeline, regulatory position, and strategic alternatives all trace back to VASCEPA/VAZKEPA [S1].

What Amarin does, in plain terms:

Amarin discovered, developed, and FDA-approved a purified EPA capsule that reduces cardiovascular events in statin-treated patients who still have elevated triglycerides. For a decade, the company built a large US commercial salesforce to market this product directly to cardiologists and primary care physicians. After generic competition entered the US market in January 2021 following patent invalidation, Amarin pivoted from a direct commercial model to a partner-driven international model. By 2025, the company had eliminated its entire US salesforce and European commercial team and handed off all active promotion to third-party pharmaceutical partners. In its current form, Amarin is a royalty/milestone/supply company that manufactures VASCEPA/VAZKEPA (via contract manufacturers) and supplies it to commercial partners who bear all marketing and distribution costs [S1, S2].

Current operational headcount: Approximately 80 employees globally [S2].

Market capitalization: ~$319M as of June 2026, with ~$302-308M in net cash, implying an enterprise value of approximately $17-20M [S2, S3].

2. Value Chain Layer Map

Amarin's value chain is best understood as a series of stages where the company's active role has progressively narrowed from near-full vertical control (2013-2020) to upstream-only (2025+):

Layer 1: R&D and Intellectual Property (Amarin-owned)

• What Amarin controls: The patent estate and regulatory exclusivities for icosapent ethyl. This includes the key REDUCE-IT FDA approval (December 2019), European Commission approval (March 2021), and a European patent extending market exclusivity to 2039 [S1].
• What Amarin does not control: The Mochida-supplied IP on underlying EPA science (Amarin licenses from Mochida). A February 2025 license agreement expanded the Mochida collaboration for additional IP [S1].
• Key risk at this layer: The U.S. MARINE-indication patents were invalidated in 2020 (federal court ruling); the REDUCE-IT CV indication patents faced the Hikma inducement litigation, which concluded with a 9-0 Supreme Court ruling in Hikma's favor on June 4, 2026, eliminating Amarin's last active litigation lever in the US [S3].

Layer 2: Manufacturing (Fully Outsourced)

• Raw API suppliers: Amarin sources icosapentaenoic acid from a limited number of external API manufacturers. The 10-K identifies supply chain concentration as a key risk [S1].
• Encapsulation and packaging: Performed by contract manufacturing organizations (CMOs). Amarin owns no manufacturing facilities [S1].
• Inventory function: Amarin takes ownership of finished-goods inventory before distribution. As of December 31, 2025, Amarin carried $195.9M in finished goods inventory — approximately 50% approved for North America, 50% for international supply [S1]. This inventory level (~92% of annual revenue) is the most material balance sheet risk.

Layer 3: Commercial Distribution (Now Entirely Partner-Driven)

• United States: Amarin no longer has a salesforce (eliminated July 2023). Product sold through major drug wholesalers (McKesson, Cardinal, AmerisourceBergen) to retail and mail-order pharmacies. Brand supported through digital/non-personal promotion and managed care contracting only [S1, S2].
• Europe (VAZKEPA via Recordati): Since June 2025, Recordati Industria Chimica e Farmaceutica S.p.A. holds an exclusive long-term license and supply agreement covering 59 European countries. Recordati handles all European marketing, medical education, pharmacovigilance, and commercial operations [S1]. Amarin supplies finished product to Recordati and receives supply revenue plus milestone payments.
• Rest of World: Covered through regional partnerships (see Section 4).

Layer 4: Patient/Physician Demand Generation

• Residual US demand: Driven by prior prescription habits, guideline recommendations from ACC/AHA/ESC, and managed care formulary positioning. Amarin no longer directly drives new prescriptions [S3].
• International demand: Driven by Recordati (EU) and regional partners. The Recordati model includes active sales representatives, market access teams, and physician education programs. As of Q1 2026, Recordati had launched in 10 European countries [S3].

3. Revenue Model

Amarin's revenue model has fundamentally restructured since peak 2020. The company now generates revenue through three mechanisms:

3A. Product Revenue — Supply to Partners (International)

Amarin manufactures VASCEPA/VAZKEPA and sells finished goods at transfer price to its commercial partners (Recordati, CSL Seqirus, Biologix, Lotus, Edding, HLS). Transfer price is negotiated in licensing agreements and typically provides Amarin a margin on cost of goods. This is now the dominant revenue stream going forward as US revenues decline [S1].

Key supply relationships:

• Recordati (Europe, 59 countries): Supply agreement tied to exclusive license; Amarin recognized ~$72.7M in Q2 2025 (the spike reflects the licensing fee plus supply revenue recognized at deal close) [S1, S2].
• CSL Seqirus (Australia/NZ): Commercial launch in Australia began October 2024; still early-stage contributor [S1].
• HLS Therapeutics (Canada): Commercial launch complete; ongoing supply [S1].
• Biologix (MENA): Commercial in UAE, Kuwait, Bahrain, Saudi Arabia, Qatar, Lebanon [S1].
• Edding/Eddingpharm (China): MARINE approved June 2023; REDUCE-IT approved June 2024 — supply ramp expected [S1].
• Lotus Pharmaceuticals (SE Asia + South Korea): Commercial/registration phase [S1].

3B. Product Revenue — US Branded VASCEPA

Despite generic competition since January 2021, branded VASCEPA maintains residual prescription share. As of Q1 2026, VASCEPA held ~48% of total icosapentaenoic ethyl prescriptions (branded + generic), supported by managed care formulary exclusives [S3]. US product revenues reflect: (gross branded Rx) × (net selling price) — which is substantially below list price after PBM rebates, patient co-pay assistance, and distributor fees. This stream is in secular decline [S2].

3C. Licensing, Milestone, and Royalty Revenue

• Recordati deal milestones: The June 2025 licensing agreement included an upfront payment and structured milestone schedule — described in the prompt as ~$25M upfront and up to $150M in milestones [S1 via prompt context].
• Ongoing royalties: Amarin receives royalties on net sales from international partners on a percentage basis per their licensing agreements [S1].
• Mochida collaboration: Research collaboration with milestone payments due to Mochida upon achievement; small financial contribution [S1].

Revenue mix trend: US product revenue was the dominant stream through 2022. By 2025-2026, the mix is shifting toward international supply/milestones. The Recordati deal accelerates this shift.

4. Customer and Payor Dynamics

United States — PBMs and Managed Care

The US pharmaceutical distribution chain for VASCEPA involves:

1. Wholesalers: McKesson, Cardinal Health, AmerisourceBergen act as the primary distribution intermediaries. Amarin sells to these at a gross price and accounts for chargebacks (the difference between gross and net selling price after PBM/insurer contractual discounts) [S1].

2. PBMs (Pharmacy Benefit Managers): Express Scripts (Cigna), CVS Caremark, OptumRx (UnitedHealth) control formulary placement for the majority of commercially insured US patients. VASCEPA's formulary position — whether preferred brand, non-preferred brand, or excluded — determines copay and patient access. Amarin's stated strategy is to maintain formulary exclusives with major PBMs, meaning contracts that position VASCEPA as the only covered IPE product (versus generic). Management confirmed maintaining these exclusives through 2025 and into 2026 [S3].

3. Medicare Part D: A critical payer for VASCEPA given that the cardiovascular patient population is disproportionately elderly. Medicare drug pricing negotiations (Inflation Reduction Act) and potential MFN pricing policies represent regulatory/pricing risk [S1].

4. Physicians: Cardiology and primary care physicians (PCPs) are the prescribers. With no Amarin salesforce, physician prescribing decisions are driven by clinical guidelines (ACC/AHA class IIa recommendation for IPE), prior prescription habits, and managed care formulary signals.

5. Patient economics: Amarin operates patient assistance programs to reduce out-of-pocket costs for insured and uninsured patients, supporting branded adherence [S4 via competitive landscape].

Key dynamic: Amarin must justify a brand premium over generic ICE without a salesforce to detail the clinical differentiation. The managed care exclusives are the primary tool — if a formulary excludes generic ICE and covers only branded VASCEPA, price sensitivity is reduced.

International — Partner Model

Amarin's international customer relationships are B2B (business-to-partner), not B2C:

• Recordati (59 EU countries): A major European specialty pharma company. Amarin's economic fate in Europe depends on Recordati's commercial execution — including the pace of market access filings, reimbursement approvals, and physician detailing. By Q1 2026, Recordati had launched in 10 countries with 20 dossiers filed for market access [S3]. Revenue to Amarin is supply-based (product transferred) plus milestone receipts.
• Other regional partners: HLS (Canada), CSL Seqirus (ANZ), Biologix (MENA), Edding (China), Lotus (SE Asia), Neopharm (Israel) — each represents a distinct market access dynamic and regulatory timeline [S1].

[Judgment]: The partner model eliminates Amarin's commercial execution risk (they no longer need a salesforce) but substitutes partner execution risk. Recordati's incentives are aligned (exclusive license, sunk market access investment) but Amarin has limited operational leverage over launch speed or promotional intensity.

5. Competitive Positioning

VASCEPA's Clinical Niche

VASCEPA occupies a narrow but clinically well-defined space: it is the only FDA-approved, prospectively proven omega-3 pharmaceutical for cardiovascular risk reduction in statin-treated patients with residual hypertriglyceridemia (TG 150-499 mg/dL). The REDUCE-IT trial (8,179 patients, >$300M cost) demonstrated a 25% relative risk reduction in first MACE, 26% reduction in a 3-point MACE composite, and statistically significant improvements across 8 secondary cardiovascular endpoints [S1].

Where VASCEPA Sits in the Cardiology Landscape

1. Among omega-3 pharmaceuticals: VASCEPA is the clinical standard — it is pure EPA with no DHA, which avoids the LDL-raising effect seen with EPA+DHA combinations (Lovaza/generic omega-3 ethyl esters). Lovaza is off-patent and largely irrelevant clinically for CV outcomes [S4].

2. Among TG-reducing agents: Fibrates (fenofibrate, gemfibrozil) are cheap but have failed CV outcomes trials (ACCORD, FIELD). ApoC-III inhibitors (olezarsen, plozasiran) are emerging as TG-lowering biologics but target very high TG (>500 mg/dL) and have no CV outcomes data yet — positioning them as niche escalation, not VASCEPA competitors [S4].

3. Among CV risk reduction drugs: PCSK9 inhibitors (evolocumab, alirocumab) target LDL-C — a different lipid pathway. Clinically complementary to VASCEPA. GLP-1 agonists (semaglutide, tirzepatide) also offer modest TG reduction as a secondary benefit of metabolic improvement, but are not substitutes for VASCEPA in the residual TG elevation/CV risk setting [S4].

4. Generic ICE: The primary direct competitive threat. Generic icosapentaenoic ethyl entered in January 2021 (Hikma, and later 8+ other manufacturers). Generic ICE is clinically identical to VASCEPA but lacks the branded positioning, patient programs, and some formulary exclusives. Amarin has retained ~48-53% IPE market share despite years of generic competition by leveraging formulary exclusives, brand loyalty, and product quality differentiation [S3, S4].

VASCEPA's durable competitive advantages:

• Only FDA label for CV risk reduction in TG 150-499 population (REDUCE-IT indication)
• Pure EPA formulation — no LDL elevation, clinically differentiated from EPA+DHA
• 30+ million prescriptions dispensed — physician familiarity and prescription inertia
• ACC/AHA Class IIa recommendation and ESC guideline support for icosapent ethyl specifically
• European patent protection to 2039 — 13-year exclusivity runway internationally
• Managed care formulary exclusives in US — partially insulates brand from generic price competition [S1, S3, S4]

[Judgment]: VASCEPA's US competitive position is structurally challenged but more defensible than the revenue decline trajectory suggests. The brand retains meaningful market share because managed care exclusives effectively function as de facto exclusivity in covered patient populations. The real existential risk is not tomorrow but the multi-year erosion as exclusive contracts expire and generics deepen penetration.

6. Key Conclusions

1. Single-product risk is unambiguous. Amarin's entire commercial existence depends on VASCEPA/VAZKEPA. The Mochida pipeline collaboration is early-stage and speculative [Fact].

2. The business model pivot is structurally complete. Amarin has transformed from a commercial-stage pharmaceutical company (US salesforce, European team) into a supply/royalty/milestone vehicle. Headcount is 80 employees [Fact]. This transformation reduces operating losses but also reduces revenue growth capacity.

3. The US business is in structural decline, but not free-fall. Generic competition has been ongoing for 5 years, yet VASCEPA retains ~48% IPE market share via managed care exclusives. The June 2026 SCOTUS ruling (Hikma, 9-0) removes the litigation backstop, but does not immediately change formulary contracts [Fact/Judgment].

4. The international business (Europe/ROW) is the growth optionality, not the stabilizer. Recordati's European launch is in very early innings — $4.9M in Q1 2026 European revenue on a 59-country license is minimal penetration. The 2039 IP runway is the asset; Recordati's execution is the variable [Fact/Judgment].

5. The balance sheet is the floor, not the ceiling. $302-308M in net cash on a ~$320M market cap implies the market assigns near-zero value to VASCEPA operations. This creates an unusual floor (hard to go bankrupt with more cash than market cap) but not an obvious catalyst unless the Barclays strategic review produces a capital return or M&A transaction [Fact/Judgment].

6. Partner execution risk has replaced commercial execution risk. Amarin no longer controls the speed or quality of VASCEPA promotion globally. Every revenue upside scenario now runs through Recordati, HLS, CSL, Edding, and other partners [Judgment].

7. Source Index

Step 04 — Financial Quality

Amarin Corporation plc (AMRN)

Prepared: June 2026 | Classification: Facts unless noted | Step: 04 of 20

1. Accounting Quality Assessment

Revenue Recognition

Amarin's revenue recognition follows ASC 606 (Revenue from Contracts with Customers). Key policies:

US Product Revenue: Revenue is recognized upon transfer of control to wholesalers — typically when product is shipped and accepted. Amarin must estimate and accrue significant variable consideration at the point of revenue recognition:

• Chargebacks (the difference between Amarin's list price and the contracted price paid by wholesaler to a PBM or government entity)
• Rebates to PBMs under formulary contracts
• Co-pay assistance (Amarin's patient programs reduce patient out-of-pocket; Amarin bears the cost)
• Product returns (estimated based on historical return rates)
• Medicaid rebates (government-mandated on Medicaid-covered prescriptions)

Assessment: The gross-to-net adjustment calculation for a branded drug in a highly genericized category is inherently complex. Amarin's net selling price is substantially below list price. Gross-to-net percentage is not explicitly disclosed in 10-K MD&A, but based on industry norms for branded drugs with active PBM rebate programs, gross-to-net adjustments are likely 40-60%+ of gross revenue. Any error in estimating PBM rebate liability could materially misstate revenue. There is no specific evidence of manipulation, but this is an area requiring audit scrutiny. [S1, Judgment]

International/Licensing Revenue: Upfront licensing fees and milestones are recognized when or as the distinct performance obligation is satisfied. The Q2 2025 spike ($72.7M vs. $42-50M in surrounding quarters) reflects what appears to be immediate recognition of the Recordati upfront payment upon execution of the June 2025 licensing agreement — appropriate under ASC 606 if the license was a distinct performance obligation satisfied at a point in time. Ongoing supply revenue is recognized as product is delivered. Royalties are recognized when underlying partner sales occur [S1].

Accounting quality assessment — Revenue: MODERATE CONCERN. Gross-to-net estimates for branded pharma are legitimately complex and subject to management judgment. The company's accrued expenses balance ($149.1M at FY2025 year-end) is large relative to revenue ($213.6M) — a portion of this reflects accrued rebates and chargebacks. A revision in gross-to-net estimates could swing revenue by 5-15%. However, auditors (EY or PwC — Amarin uses a Big 4 auditor) review these estimates, and no restatements have occurred.

Inventory Valuation

VASCEPA/VAZKEPA has pharmaceutical product dating (expiry dates). Inventory is carried at the lower of cost or net realizable value (NRV). This is the single highest-quality concern in the financial statements.

Key facts:

• FY2025 inventory: $195.9M (92% of annual revenue!) [S1]
• FY2024 inventory: $230.8M (with significant write-down impact visible in FY2024 COGS: $147.2M on $228.6M revenue = 64.4% COGS ratio vs. 43% in FY2025)
• 10-K disclosure: ~50% of inventory approved for North America, ~50% for international supply [S1]
• Product dating risk: VASCEPA capsules have finite shelf life; if product cannot be sold before expiry, it must be written down

The FY2024 gross margin collapse to 35.6% was partially driven by inventory charges. The FY2025 partial recovery to 56.6% suggests the worst write-downs occurred in FY2024, but the $195.9M remaining inventory still carries significant write-down risk given:

• Annual revenue of ~$213M → if even 20% of inventory expires/cannot be sold, that is a $39M charge (18% of current revenue)
• Ongoing US volume declines reduce the ability to sell North American inventory
• International ramp timing (Recordati) is uncertain [S1, S2, Judgment]

Accounting quality assessment — Inventory: HIGH CONCERN. The $195.9M inventory balance is the most material balance sheet risk item. Any slowdown in Recordati's European commercial ramp or additional US volume deterioration could trigger further write-downs.

Stock-Based Compensation

SBC was $13.9M in FY2025 (per 10-K), declining from $17.7M (FY2024) and $15.6M (FY2023) — consistent with the headcount reduction trend [S1]. SBC is excluded from some non-GAAP presentations; the magnitude relative to operating losses is significant (SBC is ~36% of the absolute operating loss), so non-GAAP adjustments meaningfully change the picture:

• GAAP operating loss FY2025: $(50.2M)
• Less: SBC: +$13.9M
• Less: Restructuring charges: +$36.2M (largely one-time)
• Adjusted (non-GAAP) operating loss (ex-restructuring, ex-SBC): approximately $(0.1M) — near breakeven [Estimate]

Assessment: The magnitude of restructuring charges in FY2025 is legitimate (reflecting genuine one-time cost of European team elimination) but investors should note that Amarin has had significant restructuring charges in multiple consecutive years (2023, 2025), which is a yellow flag when assessing "one-time" vs. structural costs.

2. Statement-Quality Adjustments

To normalize for comparison across periods, the following adjustments are appropriate:

[Note: FY2024 inventory write-down magnitude is estimated from the gross margin collapse (FY2024 gross margin 35.6% vs. 56.6% in FY2025 and 53.9% in FY2023); Amarin does not separately disclose inventory write-down line items in the income statement — they flow through COGS.]

Normalized operating loss (FY2025, excluding restructuring + inventory write-downs):

• GAAP operating loss: $(50.2M)
• Add: Restructuring: +$36.2M
• Normalized operating loss: $(14.0M)
• Add: SBC (for cash earnings): +$13.9M
• Cash operating income (ex-SBC): approximately $(0.1M) — near breakeven [Estimate]

3. Normalized Earnings Analysis

GAAP vs. Cash Earnings vs. Operating Burn

[S2, S3]

Analysis:

The divergence between GAAP net loss and positive operating cash flow in FY2025 and FY2023 requires explanation:

• FY2025: GAAP net loss $(38.8M) but OCF +$6.7M. The difference is driven by: (a) non-cash SBC +$13.9M; (b) non-cash D&A +$2.6M; (c) inventory drawdown releasing cash (+$34.9M change in inventories); (d) restructuring charges that are partially non-cash or have deferred cash settlements
• FY2022: The massive -$180.7M OCF reflects Amarin building inventory during the generic transition period while simultaneously operating at an operating loss — a double cash drain

Key insight: AMRN's "true" cash burn rate is more accurately measured by OCF than GAAP net income. On an OCF basis, the company has already turned positive. FCF of +$9.3M in FY2025 and +$25.6M TTM (Q2 2025 - Q1 2026) suggests the cash base is stable, not melting. The management guidance of full-year 2026 positive cash flow is credible on current trajectory [S3, Judgment].

Net cash is the dominant balance sheet story: $302.6M (FY2025 year-end), $307.8M (Q1 2026). At ~$14.29-14.52 per share, net cash covers 94-95% of the recent ~$15.24 stock price. The operational franchise trades at an implied EV of $12-17M — a near-zero valuation. This is either the biggest opportunity (if the franchise has any residual value) or an appropriate reflection of a declining business burning through its cash balance (which is NOT occurring on an OCF basis) [S2, S3, Judgment].

4. Balance Sheet Quality

Cash and Short-Term Investments: HIGH QUALITY

• Cash and equivalents: $134.7M (FY2025 year-end) [S1]
• Short-term investments: $167.9M (FY2025 year-end) [S2]
• Total liquid: $302.6M
• Nature of investments: Treasury bills, money market funds, short-duration investment-grade instruments (standard pharma treasury management); no meaningful credit risk [Judgment based on typical pharma treasury management practices; specific instrument disclosure in 10-K]
• Debt: $6.1M (lease obligations only; no bank debt, no bonds, no term loans) — effectively debt-free [S2]
• Net cash per share: $14.29 (FY2025) / $14.52 (Q1 2026) [S2]

Assessment: Cash quality is excellent. No liquidity risk. The primary risk is rate of spend — the company must continue operating near cash flow breakeven to preserve the cash pile. On current trajectory (FY2025 OCF +$6.7M, FY2026 target positive), the cash is durable.

Accounts Receivable: MODERATE CONCERN

• AR balance (FY2025): $126.8M against $213.6M annual revenue = 71 days sales outstanding (DSO) [S2, Calculated]
• Normal pharmaceutical company DSO is typically 30-60 days for US wholesaler sales; 60-90 days for international partners
• The $126.8M AR is elevated relative to revenue run-rate, suggesting either: (a) large end-of-period shipments to partners; (b) normal international partner payment terms (30-90 days); (c) some collection risk

[Judgment]: DSO of ~71 days is at the high end of normal but not alarming for a company with significant international partner shipments on 60-90 day payment terms. No specific collection concerns identified. AR declined from $133.6M (FY2023) to $122.3M (FY2024) to $126.8M (FY2025) — broadly consistent with revenue trends.

Inventory: HIGH CONCERN (see also Section 1)

• FY2025: $195.9M (91.7% of annual revenue) [S1]
• Composition: ~50% North America, ~50% International (management disclosure in 10-K)
• Write-down history: Significant COGS inflation in FY2024 consistent with inventory write-downs; $336M→$259M→$166M→$196M trajectory shows high-then-declining trend as write-downs were taken and Recordati supply absorbed

Inventory write-down risk going forward: If North American inventory (estimated ~$98M) cannot be sold before product dating, write-downs will recur. Key variables: (a) US branded VASCEPA TRx trend — positive in Q1 2026 (+17%) is encouraging; (b) Recordati European supply absorption — ongoing; (c) remaining shelf life of existing inventory lots [S1, S2, Judgment].

Intangibles and Other Long-Term Assets

• Intangible assets (net): $13.4M (FY2025) vs. $18.6M (FY2024) — amortizing down [S2]
• Other long-term assets: $1.1M (FY2025) — material decline from $65.5M (FY2024) reflecting runoff of deferred tax assets, right-of-use assets from restructured leases, and/or prior-year prepayments [S2]
• No goodwill — Amarin has never made a significant acquisition; single-product organic company [S1]

Accumulated Deficit

• $1.8B+ accumulated deficit as of December 31, 2025 [S1]
• This reflects the company's entire history — years of R&D, the $300M+ REDUCE-IT trial investment, peak salesforce spending, and ongoing losses since patent invalidation
• The accumulated deficit does NOT affect cash or the ability to operate; it is primarily a carried-forward historical R&D and commercial investment. However, it eliminates the ability to pay dividends from retained earnings under Irish company law.

5. Adversarial Research Sweep

This section systematically reviews negative research claims, litigation, regulatory investigations, and other adversarial risk factors for AMRN. Each item is assessed for status and materiality.

5A. Short Selling Campaigns / Short Reports

Finding: AMRN has historically been a high short-interest stock during the peak commercialization period (2017-2021). Short reports targeted the REDUCE-IT trial design — specifically the mineral oil placebo controversy.

The mineral oil placebo debate: The REDUCE-IT trial used mineral oil as the placebo rather than a biological inert substance. Critics (notably published academic commentaries and short-side arguments) argued that mineral oil artifactually worsened lipid parameters in the placebo group, exaggerating VASCEPA's apparent benefit. The academic debate was vigorous 2018-2020. Counter-arguments: (a) FDA accepted the trial design; (b) 25% MACE reduction was consistent across multiple pre-specified subgroups; (c) >70 global medical societies adopted guideline recommendations [S1, S4].

Current short interest: ~3.03% of shares outstanding (~624,093 shares) as of June 2026 [S3] — LOW, not a high-short-interest situation. The short thesis has largely played out (revenue decline already realized).

Assessment: Short attack risk is minimal at current valuation (trading near cash value) and current short interest (~3%). The mineral oil controversy is settled academically and commercially; FDA approved the REDUCE-IT indication in 2019 and has not rescinded it. No active short campaigns identified.

5B. Regulatory Investigations or FDA Actions

Finding: None identified.

• No FDA warning letters to Amarin in any filed disclosure [S1]
• No FDA enforcement action on VASCEPA quality or promotional practices identified
• DEA scheduling: N/A (VASCEPA is not a controlled substance)
• FDA REMS: Not required for VASCEPA
• European regulatory risk: VAZKEPA is under normal post-marketing pharmacovigilance; no safety signals identified that would affect approval [S1]

Assessment: Regulatory risk is LOW for the existing product. The primary regulatory risk is NOT enforcement but rather pricing policy (IRA, MFN proposals) and reimbursement access in new European countries.

5C. Patent Litigation History and SCOTUS June 2026 Ruling

This is the most significant legal development in AMRN's history as a publicly traded company:

Chronology:

• 2015-2018: Amarin filed initial patent infringement suits against generic ANDA filers
• January 2020: Federal district court (D. Delaware) invalidated several MARINE indication patents as obvious; ruled that generic manufacturers could market ICE for TG ≥500 mg/dL indication
• January 2021: Generic ICE entered the US market (Hikma and others)
• Ongoing: Amarin pursued an induced infringement theory — even if generics could use a "skinny label" (omitting the REDUCE-IT indication), if generic manufacturers knew prescribers would prescribe for the CV indication, this constituted patent inducement
• May 2024: Federal Circuit Court of Appeals ruled in Hikma's favor on the inducement theory
• October 2025: Supreme Court granted certiorari
• June 4, 2026: Supreme Court ruled 9-0 for Hikma — generic manufacturers' "skinny label" promotions did NOT constitute induced infringement [S3]

What the ruling means:

• Removes Amarin's ability to use patent litigation as a barrier to generic competition for the CV indication
• Does NOT invalidate Amarin's composition, formulation, or method patents entirely — it narrows what constitutes inducible infringement
• Does NOT immediately force any managed care contract changes; exclusivity contracts are commercial arrangements independent of patents
• Does open the door for more aggressive generic ICE promotion for the CV indication without litigation risk

Securities litigation related to patent battles: Multiple class action lawsuits were filed against Amarin at various times alleging securities fraud related to: (a) overstatement of patent protection strength; (b) statements regarding the REDUCE-IT trial design. These are disclosed in 10-K litigation section as ongoing or settled. No material adverse outcome has been identified in filed disclosures. Management believes existing reserves are adequate [S1].

[Judgment]: The SCOTUS ruling is the definitive legal resolution of the core patent battle. Amarin has lost. The US brand defense strategy must now rely entirely on commercial mechanisms (managed care exclusives, brand loyalty, product quality).

5D. Securities Class Actions

Finding: Amarin has been subject to class action securities litigation in prior periods, primarily related to:

1. Allegations regarding REDUCE-IT trial disclosure (whether investors were adequately informed of the mineral oil placebo controversy)
2. Allegations regarding patent protection statements

Current status: The 10-K references ongoing patent litigation (LitigationCaseOne through Six per XBRL taxonomy). The 10-K notes that management believes contingent liabilities are adequately reserved but no specific settlement amounts are disclosed [S1].

Assessment: Securities litigation for a pharmaceutical company with a controversial clinical trial is common and does not represent an existential risk at the current market cap of ~$320M. The primary class action period (2019-2021, related to REDUCE-IT launch) appears to have substantially resolved without material financial impact on the company.

5E. Inventory Write-Down Risk

This is the most material unresolved financial risk:

Current situation:

• $195.9M inventory vs. $213.6M annual revenue (91.7% ratio)
• 50% North America ($98M) — subject to US demand trends
• 50% International ($98M) — subject to Recordati launch pace and other partner absorption
• Product dating risk: Pharmaceutical finished goods have finite shelf life; lots approaching expiry must be written down

Historical write-down evidence:

• FY2024 COGS was $147.2M on $228.6M revenue (64.4% rate) vs. normal 40-43% rate — implied inventory write-down of $40-55M in FY2024 [Estimate from margin analysis; not separately disclosed]
• Inventory path: $336M (FY2023) → $166M (FY2024) → $196M (FY2025) — decline of $170M over two years, absorbed in COGS or product sales

Forward write-down risk:

• If North America inventory of ~$98M cannot be sold in 12-18 months, write-downs will recur
• The Q1 2026 +17% branded Rx improvement is encouraging but must be sustained
• Recordati European supply is beginning to absorb international inventory

[Judgment]: Inventory write-down risk is HIGH in probability of some write-down, MODERATE in magnitude (likely $15-40M rather than $100M+), and meaningful to COGS/gross margin presentation. This risk is partially mitigated by the positive US Rx trends in Q1 2026 and European supply ramp.

5F. Going-Concern Analysis

Finding: No going-concern language in auditor's report or management's discussion as of FY2025 10-K.

This is notable given:

• Net losses in FY2023 (-$59M), FY2024 (-$82M), FY2025 (-$38.8M) — consecutive GAAP losses
• However, FY2025 OCF was POSITIVE (+$6.7M), and the company has $302.6M cash — equivalent to ~8-10 years of current annual cash burn at zero OCF

[Assessment]: Going concern is NOT a material risk at current cash level and trajectory. Even in a pessimistic scenario where OCF deteriorates to -$30M annually, the company has ~10 years of cash runway. The 10-K explicitly notes no going concern uncertainty [S1].

5G. Related Party Transactions

Finding:

• CEO Aaron Berg: Purchased 160,000 shares (pre-split adjusted: 8,000 post-split) at ~$0.64 (pre-split; ~$12.80 post-split equivalent) in August 2024 — open market purchase; disclosed via Form 4. This is insider buying, not a related-party concern [S3 via prompt context].
• Chairman Odysseas Kostas: Sarissa Capital background — Sarissa is a healthcare activist fund. Sarissa's involvement in AMRN may reflect activist agitation for the Barclays strategic review process. Sarissa may hold a significant beneficial interest that is disclosed in proxy/13D filings; this is a related-party disclosure point, not an accounting concern [S3 via prompt context].
• Mochida collaboration: Amarin licenses EPA IP from Mochida; milestone payments to Mochida are due upon achievement. This is an arm's-length licensing relationship, not a related-party transaction per SEC definitions [S1].

[Assessment]: No red-flag related-party transactions identified. Insider purchase by CEO is a positive signal. Sarissa Capital presence on the board via Kostas is consistent with the activist-driven Barclays strategic review process.

5H. Additional Risk Factors Not Specifically Categorized Above

• Irish company law: Amarin is incorporated in England and Wales, tax-resident in Ireland. This creates complexity in dividend/distribution mechanics; may limit capital return options [S1]
• No authorized generics: Amarin has chosen NOT to launch an authorized generic — a deliberate strategy to protect brand premium. This means Amarin captures no share of the ~52% of ICE prescriptions going to generic products [S3]
• Q2 2026 earnings risk: Next earnings report ~July 29, 2026. Q2 2026 will be compared against Q2 2025's $72.7M revenue spike (Recordati deal close). YoY comparison will show a dramatic decline unless Recordati supply is growing at 50%+ rate. This creates a likely negative headline reaction risk even if underlying operations are improving [S2, Judgment]

6. Red Flags / Green Lights Summary

Red Flags (Concerns Requiring Monitoring)

Green Lights (Positive Quality Factors)

7. Source Index